IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer
IMpower210:一项针对东亚非小细胞肺癌患者的二线阿特珠单抗与多西他赛的III期研究
期刊:Chinese Journal of Cancer Research
影响因子:6.3
doi:10.21147/j.issn.1000-9604.2024.02.01
Wu, Yi-Long; Lu, Shun; Chen, Gongyan; He, Jianxing; Feng, Jifeng; Zhang, Yiping; Jiang, Liyan; Pan, Hongming; Chang, Jianhua; Fang, Jian; Cai, Amy; Bu, Lilian; Shi, Jane; Xia, Jinjing